WEKO3
アイテム
{"_buckets": {"deposit": "051d9884-d054-4c13-bef1-b9fc1e49c4a3"}, "_deposit": {"id": "12633", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "12633"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00012633", "sets": ["456", "1029"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "6 Management Strategies of Pulmonary Embolism (Acute Pulmonary Thromboembolism : Current Perspectives)"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "175", "bibliographicPageStart": "170", "bibliographicVolumeNumber": "119", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Anticoagulation by 5~10 days of heparin followed by warfarin is the foundation of therapy for acute pulmonary embolism (PE). Heparin should be guided by monitoring activated partial throm-boplastin time (aPTT), with a prolongation of 1.5~2.0 times the upper limit of normal being appropriate. When warfarin is replaced by heparin, it should be started on the last five days of heparin treatment, since five days are required to appear an anti-thrombotic effect of warfarin. Warfarin should be used at least 6 months and the optimal INK range is 2.5~3.0. Thrombolysis by urokinase is considered when encountered with patients, who show acute life-threatening PE such as cardiac arrest or cardiogenic shock.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "布施, 一郎"}], "nameIdentifiers": [{"nameIdentifier": "84150", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00004300149.pdf", "filesize": [{"value": "666.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 666800.0, "url": {"label": "KJ00004300149.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/12633/files/KJ00004300149.pdf"}, "version_id": "4a7408cf-5030-493f-ac7a-20a86122d3e2"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Pulmonary embolism", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Thrombolysis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Anticoagulation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "肺血栓塞栓症", "subitem_subject_scheme": "Other"}, {"subitem_subject": "抗凝固療法", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会)"}, {"subitem_title": "6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1029"], "permalink_uri": "http://hdl.handle.net/10191/2529", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-05-10"}, "publish_date": "2007-05-10", "publish_status": "0", "recid": "12633", "relation": {}, "relation_version_is_last": true, "title": ["6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会)"], "weko_shared_id": null}
6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会)
http://hdl.handle.net/10191/2529
http://hdl.handle.net/10191/252945582395-8ba2-4089-9224-e1a6141759a0
名前 / ファイル | ライセンス | アクション |
---|---|---|
KJ00004300149.pdf (666.8 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-05-10 | |||||
タイトル | ||||||
タイトル | 6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 6 急性肺血栓塞栓症の治療の進歩(シンポジウム 最近の急性肺(血栓)塞栓症,第602回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pulmonary embolism | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Thrombolysis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Anticoagulation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 肺血栓塞栓症 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 抗凝固療法 | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | 6 Management Strategies of Pulmonary Embolism (Acute Pulmonary Thromboembolism : Current Perspectives) | |||||
著者 |
布施, 一郎
× 布施, 一郎 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Anticoagulation by 5~10 days of heparin followed by warfarin is the foundation of therapy for acute pulmonary embolism (PE). Heparin should be guided by monitoring activated partial throm-boplastin time (aPTT), with a prolongation of 1.5~2.0 times the upper limit of normal being appropriate. When warfarin is replaced by heparin, it should be started on the last five days of heparin treatment, since five days are required to appear an anti-thrombotic effect of warfarin. Warfarin should be used at least 6 months and the optimal INK range is 2.5~3.0. Thrombolysis by urokinase is considered when encountered with patients, who show acute life-threatening PE such as cardiac arrest or cardiogenic shock. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 119, 号 3, p. 170-175, 発行日 2005-03 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |